William Hollins, MD
Sleep Medicine · Columbia, SCNPI 1164422820
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $114,771 of the $147,470 with a category attached, or 77.8%. It is spread thinly across 41 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2019 at $103,166 and has fallen 98.4% since, to $1,687 in 2025. Among sleep medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 676 payments — averaging $218.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$35K
- Amgen$33K
- Lilly USA, LLC$31K
- Esperion Therapeutics, Inc.$14K
- Boehringer Ingelheim$12K
- Johnson & Johnson$8K
- plus $15K from 35 others
Across 19 payments — averaging $9230.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$159K
- Boehringer Ingelheim$9K
- Sanofi US Services Inc.$5K
- Amgen$1K
- Boehringer Ingelheim France S.a.s.$423
- Boehringer Ingelheim Canada Ltd.ltee$376
What the payments were for
- Consulting fees$6,1504%
- Speaking & faculty fees$114,77178%
- Travel & lodging$14,22510%
- Food & beverage$12,1458%
- Education$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$147,470 in reported general payments places this provider in the 95th percentile of 25 sleep medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 440 | $393,472 |
| Repatha SureclickEvolocumab | 291 | $246,226 |
| XareltoRivaroxaban | 242 | $237,706 |
| EntrestoSacubitril/Valsartan | 177 | $188,711 |
| JardianceEmpagliflozin | 167 | $181,245 |
| MounjaroTirzepatide | 67 | $101,935 |
| OzempicSemaglutide | 45 | $59,375 |
| TrulicityDulaglutide | 34 | $46,828 |
| VascepaIcosapent Ethyl | 62 | $38,044 |
| GlyxambiEmpagliflozin/Linagliptin | 32 | $34,949 |
| BrilintaTicagrelor | 38 | $33,991 |
| JanuviaSitagliptin Phosphate | 38 | $33,427 |
| NexlizetBempedoic Acid/Ezetimibe | 43 | $31,420 |
| FarxigaDapagliflozin Propanediol | 38 | $30,553 |
| Icosapent Ethyl | 95 | $25,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $412 | $393,472440 claims |
| Johnson & JohnsonXarelto | $7,874 | $237,706242 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $11,689 | $235,365225 claims |
| NovartisEntresto | $1,742 | $188,711177 claims |
| Lilly USA, LLCMounjaro, Trulicity | $31,145 | $148,764101 claims |
| Novo NordiskOzempic, Wegovy | $433 | $73,35456 claims |
| AstraZenecaBrilinta, Farxiga | $273 | $64,54476 claims |
| MerckJanuvia, Janumet Xr | $446 | $45,99650 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $14,153 | $43,60363 claims |
| BayerKerendia | $231 | $8,19811 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $63 | $2,86111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 sleep medicine providers in South Carolina.
Other sleep medicine in Columbia
- Rodney HarrisonColumbia$14K
- Terry GraingerColumbia$10K
- Dezmond SumterColumbia$505
- Antoinette RutherfordColumbia$446
- Luis de la CruzSpartanburg$20K
- Stephen HandAnderson$8K
- Fahd ZarroufAnderson$5K
- Robert PuchalskiLugoff$4K
- Rupa KoothirezhiSpartanburg$4K
- Jigme SethiCharlestib$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.